Brief: Adial Pharmaceuticals Says Over 50% Of Patients Complete Full 24-Week Treatment Period In ONWARD Phase 3 Trial Of AD04
30/09/2021 14:32
Sept 30 (Reuters) - Adial Pharmaceuticals Inc ADIL.O :
* ADIAL PHARMACEUTICALS ANNOUNCES GREATER THAN 50% OF
PATIENTS
EXPECTED TO COMPLETE ONWARD™ PHASE 3 TRIAL OF AD04 FOR TREATMENT
OF ALCOHOL USE DISORDER HAVE COMPLETED FULL 24-WEEK TREATMENT
PERIOD - TRIAL COMPLETION ANTICIPATED Q1 2022
Source text for Eikon: ID:nGNX8RlTKT
Further company coverage: ADIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)